Sponsor Dossier
Southern XP IP
Sponsor Dossier for Southern XP IP. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AMIKACIN
- Brand: AMPHOTERICIN LIPOSOMAL
- Brand: ATORVASTATIN-DRLA
- Brand: ATORVASTATIN-RZ
- Brand: AZACITIDINE
- Brand: BETAHISTINE
- Brand: BIVALIRUDIN
- Brand: CAMBIA
About
Southern XP IP is an Australian Private Company with ABN 55639505570, registered in Victoria. The entity status is Active.
Portfolio
Southern XP IP has 36 brands on the ARTG, of which 26 are indexable and 22 carry a Product Information document. 6 brands are PBS-listed, 0 have a PBAC outcome on record, and 6 have an AusPAR on record. Notable brands include AMIKACIN, AMPHOTERICIN LIPOSOMAL, ATORVASTATIN-DRLA, ATORVASTATIN-RZ, AZACITIDINE, BETAHISTINE, BIVALIRUDIN, CAMBIA, CEFTAZIDIME SXP, CEFUROXIME, CIZERE, CIZIGO.
Therapeutic focus
— Cardiology: 8 brands — Neurology: 7 brands — Pain Management: 6 brands — Infectious Disease: 6 brands — Gastroenterology: 2 brands — Psychiatry: 2 brands — Oncology: 2 brands — Other: 1 brand — Hepatology: 1 brand — Dermatology: 1 brand
PBS footprint
6 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest AusPAR is 2021-08-16, across 6 brands with an AusPAR on record.